Skip to main content
. 2022 Jul 4;58(7):898. doi: 10.3390/medicina58070898

Table 7.

Local and systemic treatment modalities in our cohort.

Treatment No. pts/Eyes % pts
Topical (CS+mydriatics) 201/398 85.5
Intravitreal implant 62/94 24.3
Anti-VEGF 3/3 1.3
Sistemic CS 203 86.4
CS+Azathioprine * 12 5.1
CS+Methotrexate * 29 12.3
CS+Mycophenolate M. * 43 18.3
CS+Adalimumab * 11 4.7
CS+Rituximab * 3 1.3
CS+Interferon α-2a * 4 1.7

* CS were used only in the induction phase, then slowly tapered.